cerecor
present
upcoming
investor
conferences
rockville
md
chesterbrook
globe
newswire
cerecor
nasdaq
cerc
biopharmaceutical
company
focused
becoming
leader
development
commercialization
treatments
rare
orphan
diseases
today
announced
michael
cola
president
chief
executive
officer
present
two
upcoming
virtual
conferences
wainwright
annual
global
investment
conference
date
monday
september
time
pm
et
oppenheimer
fall
healthcare
life
sciences
medtech
summit
date
monday
september
time
pm
et
live
webcast
presentations
accessed
news
events
page
investors
section
company
website
cerecor
cerecor
biopharmaceutical
company
focused
becoming
leader
development
commercialization
treatments
rare
orphan
diseases
company
advancing
pipeline
innovative
therapies
address
unmet
patient
needs
within
rare
orphan
diseases
company
rare
disease
pipeline
includes
compounds
therapies
inherited
metabolic
disorders
known
congenital
disorders
glycosylation
food
drug
administration
fda
granted
rare
pediatric
disease
designation
rpdd
orphan
drug
designation
odd
three
compounds
thus
potentially
qualifying
company
receive
priority
review
voucher
prv
upon
approval
new
drug
application
nda
company
also
developing
monoclonal
antibody
developed
treatment
severe
crohn
disease
also
clinical
trial
acute
respiratory
distress
syndrome
dual
mtor
inhibitor
developed
treatment
complex
lymphatic
malformations
granted
rpdd
odd
fda
thus
potentially
qualifying
company
receive
fourth
prv
upon
approval
nda
monoclonal
antibody
developed
treatment
autoimmune
inflammatory
diseases
adult
onset
stills
disease
multiple
myeloma
information
cerecor
please
visit
statements
press
release
may
include
statements
made
pursuant
private
securities
litigation
reform
act
statements
statements
historical
facts
statements
subject
significant
risks
uncertainties
subject
change
based
various
factors
many
beyond
cerecor
control
could
cause
actual
results
differ
statements
statements
may
include
without
limitation
statements
respect
cerecor
plans
objectives
projections
expectations
intentions
statements
identified
words
projects
may
might
could
would
continue
seeks
aims
predicts
believes
expects
anticipates
estimates
intends
plans
potential
similar
expressions
including
use
negative
discussions
future
matters
development
product
candidates
products
timing
success
trial
results
regulatory
review
potential
attributes
benefits
product
candidates
statements
historical
statements
based
upon
current
beliefs
expectations
cerecor
management
subject
significant
risks
uncertainties
including
drug
development
costs
timing
risks
including
reliance
investigators
enrollment
patients
clinical
trials
might
slowed
pandemic
regulatory
risks
cerecor
cash
position
potential
need
raise
additional
capital
general
economic
market
risks
uncertainties
including
caused
pandemic
risks
detailed
cerecor
filings
securities
exchange
commission
actual
results
may
differ
set
forth
statements
except
required
applicable
law
cerecor
expressly
disclaims
obligations
undertaking
release
publicly
updates
revisions
statements
contained
herein
reflect
change
cerecor
expectations
respect
thereto
change
events
conditions
circumstances
statement
based
media
investor
inquiries
james
harrell
investor
relations
chief
commercial
officer
cerecor
jharrell
office
